Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure

Shukla, Nilima; Angelini, Gianni D; Ascione, Raimondo; Talpahewa, Sudath; Capoun, Radek; Jeremy, Jamie Y.

doi:10.1016/s0003-4975(02)04892-0

Cited by 35 publications

(17 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data confirm that NCX 4016 had significant dosedependent vasodilatory effects on VGs [7,8]. For the first time, even in a limited number of patients, we report that this NO-induced VGs vasodilation which was equally effective in DM and NDM patients.…”

Section: Discussionsupporting

confidence: 83%

“…This effect was obtained, even if of lesser magnitude, also in vascular preparations with no or damaged endothelium. Shukla et al have recently reported about the capacity of three NORA drugs (NCX 4040, NCX 4050, NCX 4060) to reduce, in vitro, the human saphenuos vein spasm and neointima formation [7], but no information, to our knowledge, is available with regards to NORA in the presence of damaged or impaired VG endothelium. NCX 4016 tested in our study confirmed the effectiveness of NORA in terms of vasodilative response of human saphenuos veins, also in the presence of structural damage of the endothelium.…”

Section: Discussionmentioning

confidence: 98%

“…NORA has been shown to elicit significant vascular (arterial) relaxing response, to protect endothelial cells against apoptosis and to reduce oxidative stress in experimental studies [7,8,16,17]. NCX 4016, a recently synthetized NORA, has been suggested to reduce restenosis after percutaneous transluminal coronary angioplasty, in experimental models [18].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, a new family of nitric oxide-donating non-steroid anti-inflammatory drugs has been described. These compounds showed to enhance antiinflammatory, antithrombotic, and analgesic effects of the parent drugs [7][8][9][10][11][12][13]. Therefore, we sought to elucidate the effects of NO-releasing aspirin (NORA) in terms of evoked functional response of venous segments harvested in DM or control patients undergoing CABG.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG

Lorusso¹,

Cicco²,

Beghi³

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 83%

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG

Lorusso¹,

Cicco²,

Beghi³

et al. 2007

International Journal of Cardiology

View full text Add to dashboard Cite

“…SMC gene therapy of nitric oxide synthase in injured arteries in rats and adventitial delivery of a nitric oxide donor to vein grafts in fat-fed rabbits reduced neointimal formation [120,149], and this therapy is now being extended into clinical trials [139]. Ex vivo experiments indicate that nitric oxide-donating aspirins may be suitable to prevent thrombosis, spasm and possibly neointimal formation in vein grafts [33,285]. Vein grafts have increased superoxide levels upon exposure to the arterial environment, and this is known to quench nitric oxide [286].…”

Section: Antioxidantsmentioning

confidence: 99%

Targeted Treatments for Restenosis and Vein Graft Disease

Thomas

2012

ISRN Vascular Medicine

View full text Add to dashboard Cite

Surgery to restore blood flow in arteries blocked by atherosclerotic plaque is a common treatment in cardiovascular disease. Longterm complications of surgical treatment are vein graft disease and restenosis, a renarrowing of the blood vessel after bypass or removal of the culprit atherosclerotic plaque. Attempts to prevent or treat these complications by systemic pharmacological approaches have been largely unsuccessful in the clinic. This has led to an interest in developing targeted or locally delivered strategies. This paper discusses many of the various site-delivered therapies that are under examination as potential antirestenotic and antivein graft disease agents (including antithrombotic, antiproliferative, and anti-inflammatory agents) and why many therapies developed in animal models fail in clinical trials. Techniques of targeted delivery (including stents, "magic bullets," and adventitial delivery) and delivery systems (including nanoparticles and the use of gene therapy) are also discussed.

show abstract

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Pereira-Leite

Nunes

Jamal

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

The efficacy of nonsteroidal anti-inflammatory drugs (NSAIDs) against inflammation, pain, and fever has been supporting their worldwide use in the treatment of painful conditions and chronic inflammatory diseases until today. However, the long-term therapy with NSAIDs was soon associated with high incidences of adverse events in the gastrointestinal tract. Therefore, the search for novel drugs with improved safety has begun with COX-2 selective inhibitors (coxibs) being straightaway developed and commercialized. Nevertheless, the excitement has fast turned to disappointment when diverse coxibs were withdrawn from the market due to cardiovascular toxicity. Such events have once again triggered the emergence of different strategies to overcome NSAIDs toxicity. Here, an integrative review is provided to address the breakthroughs of two main approaches: (i) the association of NSAIDs with protective mediators and (ii) the design of novel compounds to target downstream and/or multiple enzymes of the arachidonic acid cascade. To date, just one phosphatidylcholine-associated NSAID has already been approved for commercialization. Nevertheless, the preclinical and clinical data obtained so far indicate that both strategies may improve the safety of nonsteroidal anti-inflammatory therapy.

show abstract

Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure

Cited by 35 publications

References 20 publications

Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG

Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG

Targeted Treatments for Restenosis and Vein Graft Disease

Nonsteroidal Anti‐Inflammatory Therapy: A Journey Toward Safety

Contact Info

Product

Resources

About